// App-Quantinova.ai

622 : A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors

Researchers

Presenter

  • David Pinato

Principal Investigators

  • Ruth Plummer

  • Martin Gutierrez

  • Jeffrey Yachnin

  • Aglaia Schiza

  • Martin Hojgaard

  • Knut Smeland

  • William Edenfield

  • Hans Prenen

  • Lars Ny

  • Alan Anthoney

  • Nuria Kotecki

  • Stefan Symeonides

  • Louis Viviers

  • Jeannie Daniel

  • Jennifer Pulini

  • Udai Banerji

Medical Centers

  • Institute Jules Bordet, Brussels, Belgium

  • Uppsala University Hospital, Uppsala, Sweden

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Incyte Corporation, Wilmington, DE

  • HACKENSACK UNIVERSITY MEDICAL, Hackensack, NJ

  • University of Edinburgh, Edinburgh, UK

  • StJamess University Hospital, Leeds, UK

  • Karolinska University Hospital, Stockholm, Sweden

  • Royal Marsden Hospital NHS Trust, London, UK

  • University Hospital Antwerp, Edegem, Antwerp, Belgium

  • Newcastle Hospital NHS Foundation Trust, Newcastle-upon-Tyne, UK

  • Oslo University Hospital, Oslo, Norway

  • Prisma Cancer Institute, Greenville, NC, USA

  • Imperial College Healthcare NHS Trust, London,

Locations

  • Belgium

  • United States

  • United Kingdom

  • Sweden

  • Denmark

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT04272034

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved